Clinical Trials Browser

Phase 3 × zalutumumab × Head & Neck × Clear all

NCT00496652 2016-11-25

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Phase 3 Completed

Head and Neck Neoplasms

NCT00382031 2013-10-15

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Phase 3 Completed

286 enrolled 12 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell